Suchergebnisse

Lush, L.: Why do the poor lack access to essential medicines? - S. 1-20 Preker, A. S.: From health to wealth and back to health. - S. 21-41 Conroy, A. C. ...: Responding to health crises : the frustrations of a small African country. - S. 45-63 Attridge, J.; Atun, R.: Economy regulatory frameworks for the pharmaceutical sector in middle-income countries. - S. 64-106 Heaton, A.: Joint public-private initiatives and developing-country health systems. - S. 109-115 Sturchio, J. L.: Partnership for action : the experience of the Accelerating Access Initiative, 2000-04, and lessons learned. - S. 116-151 Besten, H.; Gonzi, J.: Non-profit drug distribution : the experience of the International Dispensary Association. - S. 152-160 Attaran, A.: Understanding patents and out-licensing in the procurement of anti-retroviral medicines. - S. 161-171 Attaran, A.; Granville, B.: Who needs to do what? - S. 175-192

The starting point of this project is the question of whether the macroeconomics of the German political establishment does indeed differ, as it often seems to do, from standard textbook macroeconomics: in particular, the former appears to neglect demand management (although it may be quite interventionist in other ways), to reject debt relief and to emphasise structural reform designed to improve competitiveness as the (only) key to economic growth. How far is this true? How much of whatever difference exists is due to a well worked out set of ideas in the form of Ordoliberalism? How does it relate to Germany's own experiences in different periods? How far is this the result of political preferences and how much do the idiosyncrasies of these German views matter, for the development of the Eurozone and indeed the health of the German economy?